Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Lactose Intolerance
Interventions: Lactobacillus acidophilus MPH734, Placebo; Dietary Supplement
Lead sponsor: Lemuel W. Taylor IV; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Osteoarthritis, Knee
Interventions: FDS-Strawberry, Placebo; Dietary Supplement
Lead sponsor: Oklahoma State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions: AXS-12 (Reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more

Conditions: Healthy, Elderly
Interventions: PF-04447943; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 29
States / cities: Escondido, California • Greenbrae, California • Los Angeles, California + 25 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions: Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more

Conditions: Multiple Sclerosis
Interventions: Emotional Processing Training, Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cradle Cap, Infantile Seborrheic Dermatitis
Interventions: Promiseb Topical Cream, Bland emollient; Device · Other
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 30 Days and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Norwich, Connecticut • Louisville, Kentucky • Newark, New Jersey + 1 more

Conditions: Cardiovascular Disease, Inflammation
Interventions: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA); Biological
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 45 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: LAF 237; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Conditions: Breast Cancer, Depression, Fatigue, Sleep Disorders
Interventions: Metformin, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 252
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 185 more

Conditions: TQT Study
Interventions: Tetrodotoxin, Placebos; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
Interventions: Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Cannabis Use
Interventions: Cannabis, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Asthma
Interventions: Montelukast 10 mg orally, Placebo; Drug · Other
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Hyperlipidemia
Interventions: Plant sterol, Placebo; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 30 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 38
States / cities: San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more

Conditions: COVID-19
Interventions: vitamin D, Placebo; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,024 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

Strawberries and Knee Osteoarthritis (OA)

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Remediation of Emotional Processing Deficits in MS

Promiseb Topical Cream for Cradle Cap

Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation

Acute Metabolic Effects of LAF 237 in Type 2 Diabetics

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Asthma in the Elderly: The Effect of Montelukast

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

Vitamin D for COVID-19 Trial

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.